Results 151 to 160 of about 4,805 (202)

Efficacy and safety of selinexor-based regimens as first-line treatments for elderly patients with diffuse large B-cell lymphoma: a real-world study. [PDF]

BMC Cancer
Li J, Ge J, Chen T, Cao J, He X, Wang S, Yang H, Wang Y, Sun P, Huang J, Liu S, Li Z.   +11 more
europepmc   +1 more source

Selinexor, a selective inhibitor of nuclear export, shows anti-proliferative and anti-migratory effects on male germ cells in vitro. [PDF]

BMC Pharmacol Toxicol
Öztatlıcı M, Zada PR, Çolaksel RB, Halıcıoğlu BŞ, Öztatlıcı H.   +4 more
europepmc   +1 more source

Modulation of anti-tumour immunity by XPO1 inhibitors. [PDF]

Explor Target Antitumor Ther
Fisher JG, Bartlett LG, Kashyap T, Walker CJ, Khakoo SI, Blunt MD.   +5 more
europepmc   +1 more source

Selinexor combination with decitabine and half-dose CMG (Cytarabine+ Mitoxantrone+G-CSF) in Patients with refractory/relapsed acute myeloid leukemia (AML) previously exposed to Venetoclax: a single-center retrospective study. [PDF]

Leuk Res Rep
Zhao ZY, Zhang XL, Zhan Y, Zuo YB, Li JA, Ren JH, Guo XL, Nie ZY.   +7 more
europepmc   +1 more source

Phase I Trial of Selinexor in Pediatric Recurrent/Refractory Solid and CNS Tumors (ADVL1414): A Children's Oncology Group Phase I Consortium Trial. [PDF]

Clin Cancer Res
Green AL, Minard CG, Liu X, Safgren SL, Pinkney K, Harris L, Link G, DeSisto J, Voss S, Nelson MD, Reid JM, Fox E, Weigel BJ, Glade Bender J.   +13 more
europepmc   +1 more source

Selinexor for multiple myeloma.

Australian prescriber
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Selinexor for Refractory Multiple Myeloma

New England Journal of Medicine, 2019
Kenar D Jhaveri
exaly   +3 more sources